Literature DB >> 26795392

[Reduction of relapse in the radiation area by adjuvant lymph-node field radiotherapy in metastatic malignant melanoma patients at high risk of recurrence].

Ralf Gutzmer1, Hans Christiansen2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26795392     DOI： 10.1007/s00066-015-0936-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  2 in total

1.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Cyril Konto; Axel Hoos; Veerle de Pril; Ravichandra Karra Gurunath; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  Lancet Oncol       Date:  2015-03-31       Impact factor: 41.316

2.  Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

Authors:  Bryan H Burmeister; Michael A Henderson; Jill Ainslie; Richard Fisher; Juliana Di Iulio; B Mark Smithers; Angela Hong; Kerwin Shannon; Richard A Scolyer; Scott Carruthers; Brendon J Coventry; Scott Babington; Joao Duprat; Harald J Hoekstra; John F Thompson
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.